Ph- Acute Lymphoblastic Leukemia (Ph-ALL)
5 clinical trials · Condition
◉ Watch Ph- Acute Lymphoblastic Leukemia (Ph-ALL)
| Record | Firm | Date |
|---|---|---|
| Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial (NCT07643103) | Institute of Hematology & Blood Diseases Hospital, China | 2026-06-12 |
| Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML (NCT07493408) | The University of Hong Kong | 2026-03-30 |
| Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL (NCT06658925) | Institute of Hematology & Blood Diseases Hospital, China | 2024-11-01 |
| Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies (NCT03414450) | EDDC (Experimental Drug Development Centre), A*STAR Research Entities | 2018-04-25 |
Track Ph- Acute Lymphoblastic Leukemia (Ph-ALL) automatically
Every clearance here is in the API, with alerts when new ones post.